AUTHOR=Ottaiano Alessandro , Capozzi Monica , Tafuto Salvatore , De Stefano Alfonso , De Divitiis Chiara , Romano Carmela , Avallone Antonio , Nasti Guglielmo 

TITLE=Folfiri-Aflibercept vs. Folfiri-Bevacizumab as Second Line Treatment of RAS Mutated Metastatic Colorectal Cancer in Real Practice

JOURNAL=Frontiers in Oncology

VOLUME=9

YEAR=2019

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2019.00766

DOI=10.3389/fonc.2019.00766

ISSN=2234-943X

ABSTRACT=<p><bold>Background:</bold> There are no clinical studies comparing the efficacy of bevacizumab vs.aflibercept in association with folfiri in RAS mutated (RAS-M) metastatic colorectal cancer patients (mCRC) pretreated with folfox and bevacizumab.</p><p><bold>Patients and Methods:</bold> Consecutive RAS-M unresectable mCRC patients progressing to first-line folfox/bevacizumab were treated with 12 cycles of folfiri/bevacizumab (arm A) or folfiri/aflibercept (arm B) at Oncologist discretion. Differences in overall survival between the two schedules were analyzed. Responses and toxicities were described with RECIST and NCI-CTC v4.0, respectively.</p><p><bold>Results:</bold> Seventy-four patients were treated from January 2014 to January 2018; 31 with arm A, 43 with arm B. Among clinical factors there was a predominance of more extended disease (&gt;2 metastatic sites) in arm B (26/43 [60.5%] vs. 10/31 [32.2%] arm A; <italic>p</italic> = 0.0414). Fifty-nine patients were evaluable for response: arm A, 5 PR (Partial Response), 15 SD (Stable Disease), 8 PD (Progressive Disease); arm B, 5 PR, 16 SD, 10 PD. There were no grade 4 toxic events. Duration of first-line chemotherapy was significantly shorter in patients treated in arm B (12 pts &lt;6 months, 16 pts ≥6, and &lt;12, 15 pts ≥12) vs. arm A (1 pts &lt;6 months, 14 pts ≥6, and &lt;12, 16 pts ≥12) (<italic>p</italic> = 0.0210); these patients were excluded from survival analysis to avoid prognostic interferences. No maintenance treatment with aflibercept was done in arm B while in arm A bevacizumab with or without fluorouracil and folinic acid were allowed. Median OS were 8.9 months in arm A vs. 12.1 months in arm B (+3.2 months; <italic>p</italic> = 0.9331, HR: 1.02; 95% CI: 0.57–1.84). Six-months survivals were 65% in arm A and 80% in arm B.</p><p><bold>Conclusions:</bold> Folfiri/bevacizumab and folfiri/aflibercept are equally effective second-line therapies in RAS-M mCRC patients. Although not significant, folfiri/aflibercept was associated with a lower risk of death particularly during the 6-months induction phase.</p>